r CLRB Stock Quote - Cellectar BioSciences, Inc. Stock Price Today
TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds

Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
CLRB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-1.14%78.631.2%$610.28m
AMGNAmgen Inc.
0.16%178.241.2%$580.48m
GILDGilead Sciences, Inc.
-0.22%67.380.9%$546.51m
BIIBBiogen Inc.
0.63%286.211.2%$492.50m
REGNRegeneron Pharmaceuticals, Inc.
-0.30%293.742.6%$304.95m
ILMNIllumina, Inc.
-1.70%266.223.5%$224.24m
VRTXVertex Pharmaceuticals Incorporated
0.34%157.501.9%$224.02m
ALXNAlexion Pharmaceuticals, Inc.
0.51%117.742.0%$217.12m
AAgilent Technologies, Inc.
-1.50%63.161.5%$202.56m
NKTRNektar Therapeutics
-0.77%79.966.0%$187.29m
INCYIncyte Corporation
2.64%68.432.5%$156.91m
SRPTSarepta Therapeutics, Inc.
1.85%91.6516.6%$126.97m
BMRNBioMarin Pharmaceutical Inc.
4.77%92.494.4%$126.25m
EXASExact Sciences Corporation
-1.95%51.8225.5%$106.23m
BLUEBluebird Bio, Inc.
0.62%188.1515.7%$96.83m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micrometastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on April 11, 2011 and is headquartered in Madison, WI.